ERBB2 and cancer: These are clinically significant findings, suggesting that current use of PI3K/AKT inhibitors in either unselected HER2+ cancer patients, or based on PIK3CA and PTEN mutations may be sub-optimal [8], and some HER2+ patients may benefit from treatment MEK inhibitors.